Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics Awarded $742,000 SBIR Grant for Liver Metabolomics

NEW YORK, June 21 (GenomeWeb News) - Paradigm Genetics has received a $742,000 phase I/II SBIR contract from the National Institute of Environmental Health Sciences for an effort to use metabolomics to discover biochemical pathways of drug-induced liver injury, the company said today.

 

The contract, "Metabolomics and Pathway Linkage: Urine, Serum, and Liver," includes $99,000 in funding for phase I, which is expected to run for six months,  $643,000 for phase II, which is expected to run for two more years and will be awarded upon the completion of phase I. The contract is being awarded under the NIH Fast Track program, which is used to expedite awards for applications with high commercialization potential.

 

Under the contract, Paradigm will use mass spectrometry to conduct pre-clinical studies on three compounds known to cause liver damage, and will profile hundreds of small molecular weight biochemicals with a potential link to liver toxicity. The findings could lead to diagnostics and drug screening tools to provide earlier signals of liver injury, the company said.

 

" Paradigm's objective through this study is to identify non-invasive biomarkers that are more sensitive predictors of the early onset of liver injury," Thomas Colatsky, vice president of human health research at Paradigm Genetics, said in a statement. "These biomarkers may be useful as diagnostics that will help pharmaceutical companies to better assess drug candidate safety."

 

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.